# Compare KPV, MOTS-c, PT-141, Retatrutide, and Thymosin Alpha-1 — Peptides Jobs

> A side-by-side comparison of five Research Peptide Fundamentals research peptides — KPV, MOTS-c, PT-141, retatrutide, and thymosin alpha-1 — across functional job, evidence stage, regulatory status, and key caution.

How KPV, MOTS-c, PT-141, retatrutide, and thymosin alpha-1 differ in mechanism, evidence stage, regulatory status, and the caution that matters most for each.

## Abstract — the short version

The five compounds on this desk do not share a chemical class — they are grouped instead by the fact that each performs a distinct, well-defined biological *job*. Read side by side, the comparison clarifies what 'job' means at a molecular level: a receptor switched on, a transporter engaged, an enzyme activated, a transcription factor turned on or suppressed. This page reports what was studied and where each compound's evidence currently stands, not what any individual should take; no dose recommendation appears anywhere on this page.

## The comparison matrix

| Dimension | KPV | MOTS-c | PT-141 (bremelanotide) | Retatrutide | Thymosin Alpha-1 |
| --- | --- | --- | --- | --- | --- |
| Functional job | Anti-inflammatory signaling at the gut lining | Mitochondrial energy-metabolism signaling | Central nervous system signaling for sexual desire | Whole-body metabolic hormone regulation | Adaptive immune-system priming |
| Peptide class | Melanocortin-derived anti-inflammatory tripeptide | Mitochondrial-derived peptide (MDP) | Melanocortin (MC3R/MC4R) receptor agonist | GIP/GLP-1/glucagon triple receptor agonist | Thymic immunomodulatory peptide |
| Evidence stage | Cell and animal studies only; no human trials [5] | Cell/animal studies plus one human observational biomarker study [7] | FDA-approved; two Phase 3 RCTs plus a long-term extension [13][14] | Phase 2 complete; Phase 3 ongoing, not yet reported [16] | Approved abroad; large human RCTs including a 2025 Phase 3 null result [21][22] |
| Regulatory status | Research chemical only; no approved use anywhere | Research chemical only; no approved use anywhere; prohibited in organized sport | FDA-approved (HSDD in premenopausal women only) [15] | Investigational; not approved anywhere as of mid-2026 [16] | Approved (thymalfasin) in 35+ countries; not FDA-approved [22] |
| Key caution | No human safety data exist at any dose [5] | No validated human pharmacokinetics; prohibited in organized sport | Approved only for one indication; all other use is off-label [13][15] | Unverified gray-market supply; dose-dependent heart-rate increase [19] | Largest trial (sepsis) was null; temper expectations accordingly [21] |

## Functional job

Each compound's job maps to a distinct tier of biology. KPV's job is local: it acts at the gut epithelial barrier, engaging a transporter (PepT1) and suppressing inflammatory signaling pathways in place. MOTS-c's job is intracellular: it operates inside the cell, at the mitochondrion-nucleus interface, tuning energy metabolism. PT-141's job is central: it acts on brain circuits governing motivation and desire, not on peripheral tissue. Retatrutide's job is systemic and hormonal: it engages three separate metabolic receptors across the body to shift both appetite and energy expenditure. Thymosin alpha-1's job is the broadest in immunological scope: it acts on dendritic cells and T cells to reshape how the entire adaptive immune system communicates.

## Evidence stage

The five sit at very different points on the evidence ladder. KPV and MOTS-c have no human interventional data at all — every efficacy claim is a cell or animal result [5][8]; MOTS-c additionally has one human observational cohort linking a blood biomarker to clinical outcomes, which is an association rather than a treatment record [7]. PT-141 and thymosin alpha-1, by contrast, both carry substantial human randomized-trial evidence, though for different reasons: PT-141/bremelanotide has FDA-approved-drug-grade Phase 3 data [13][14], while thymosin alpha-1 has decades of trials conducted for its international approval, including recent large trials that returned mixed and, in one 2025 case, null results [21][22]. Retatrutide sits in between: its Phase 2 program is complete and its efficacy signal is strong, but Phase 3 confirmation has not yet been reported [16].

## Regulatory and approval status

Of the five, only PT-141/bremelanotide is FDA-approved, and only for one specific indication [15]. Thymosin alpha-1 is approved as a drug in more than 35 countries but carries no US marketing approval [22]. Retatrutide has no approval anywhere and remains investigational while Phase 3 trials continue [16]. KPV and MOTS-c have no approved status in any jurisdiction and are available only as laboratory research chemicals; MOTS-c additionally carries a prohibited status in organized sport under anti-doping rules.

## Key caution

For KPV, the defining caution is simply the absence of any human safety data — there is no dose, efficacy, or safety profile established in people at all [5]. For MOTS-c, it is the same evidentiary gap combined with a sport-specific prohibition. For PT-141, the caution is scope: it is approved for one narrow indication, and every other use is off-label [13][15]. For retatrutide, the caution is supply and cardiovascular monitoring — gray-market material cannot be verified, and a documented dose-dependent heart-rate increase warrants attention [19]. For thymosin alpha-1, the caution is expectation management: the largest, most rigorous trial conducted to date, in sepsis, found no significant benefit, and that result should temper enthusiasm generated by smaller, earlier studies [21].

---

This is an editorial literature review of research peptides' biological functions, written for scholarly orientation — not a clinic, not a supplier, and not a substitute for professional medical guidance.